（二）召集人：浙江佐力药业股份有限公司（以下简称"公司"）董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东大会届次：2024 年第一次临时股东大会 证券代码：300181 证券简称：佐力药业 公告编号：2024-072 浙江佐力药业股份有限公司 关于召开 2024 年第一次临时股东大会通知的公告 （三）会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、 行政法规、部门规章、规范性文件和公司章程的相关规定。 （四）会议召开的日期和时间 1、现场会议召开时间：2024 年 11 月 20 日（星期三）下午 14:00 2、网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统进 行网络投票的具体时间为：2024 年 11 月 20 日（星期三）上午 9:15—9:25，9:30— 11:30 和下午 13:00—15:00；通过深交所互联网投票系统投票的具体时间为：2024 年 11 月 20 日（星期三）上午 9:15 至下午 15:00 期间的任意时间。 （五）会议的召开方式：现场投票与网络投票相结合 ...

证券代码：300181 证券简称：佐力药业 公告编号：2024-068 浙江佐力药业股份有限公司 第八届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江佐力药业股份有限公司（以下简称"公司"）第八届董事会第三次会议 于 2024 年 10 月 25 日在公司会议室以现场和通讯表决相结合的方式召开。会议 通知于 2024 年 10 月 15 日以专人送达、电话、传真及电子邮件等相结合方式送 达各董事。会议应出席董事 9 人，实际出席董事 9 人（其中独立董事朱建先生以 通讯表决方式审议表决）。会议由公司董事长俞有强先生主持，公司监事、高管 列席会议。会议的召开符合《公司法》、《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于<公司 2024 年第三季度报告>的议案》 经审议，董事会认为：公司《2024 年第三季度报告》的编制和审核程序符 合相关法律法规，报告内容真实、准确、完整地反映了公司经营的实际情况，不 存在虚假记载、误导性陈述或重大遗漏。 《2024 年第三季度报告》具体内容详见公司同日披 ...

浙江佐力药业股份有限公司 2024 年员工持股计划管理办法 本员工持股计划的持有人是根据《公司法》《证券法》《指导意见》《自律监 管指引》等有关法律、法规、规范性文件及《公司章程》的相关规定而确定。公 司员工按照依法合规、自愿参与、风险自担的原则参加本员工持股计划。 所有参与对象必须在本员工持股计划的存续期内，与公司（含控股子公司， 下同）签署劳动合同或聘用合同。 （二）激励对象确定的职务依据 本员工持股计划的参加对象应符合以下标准之一： 1、公司董事（不含独立董事）、监事、高级管理人员； 2、核心营销人员和核心技术人员； 3、经董事会认定的其他人员。 符合条件的员工按照依法合规、自愿参与、风险自担的原则参加本员工持股 计划。 为规范浙江佐力药业股份有限公司（以下简称"佐力药业"或"公司"）2024 年员工持股计划（以下简称"员工持股计划"、"员工持股计划"或"本计划"） 的实施，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《中国证监会关于上市公司实施员工持股 计划试点的指导意见》（以下简称"《指导意见》"）、《深圳证券交易所上市公司自 律监管 ...

Financial Performance - The company's operating revenue for Q3 2024 reached ¥616,624,658.40, representing a 35.97% increase compared to the same period last year[2]. - Net profit attributable to shareholders for the same period was ¥125,426,028.33, up 40.61% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥122,964,581.10, reflecting a 41.17% increase from the previous year[2]. - Total operating revenue for the period reached CNY 2,044,879,347.76, a significant increase of 39.5% compared to CNY 1,464,947,132.50 in the previous period[20]. - Net profit for the period was CNY 427,382,283.28, representing a 46.0% increase from CNY 292,583,698.54 in the same period last year[21]. - Basic earnings per share increased to CNY 0.6018, compared to CNY 0.4090 in the previous period, reflecting a growth of 47.0%[22]. - Comprehensive income for the period was CNY 393,943,478.14, compared to CNY 170,623,591.54 in the previous period, reflecting a substantial increase of 130.7%[22]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,872,439,027.99, a 6.77% increase from the end of the previous year[2]. - The company's equity attributable to shareholders decreased to ¥2,599,700,232.89, down 4.73% from the end of the previous year[2]. - Total liabilities increased to CNY 1,231,183,875.67, compared to CNY 853,092,322.35 in the previous period, indicating a growth of 44.3%[21]. - Deferred income rose to CNY 21,764,990.99 from CNY 19,896,586.81, marking an increase of 9.3%[21]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥214,125,849.27, showing a decline of 4.39% compared to the same period last year[2]. - The net cash flow from operating activities for Q3 2024 was ¥214,125,849.27, a decrease of 4% compared to ¥223,951,981.61 in Q3 2023[24]. - The total cash outflow from operating activities amounted to ¥1,699,968,873.74, up 20.5% from ¥1,410,316,284.08 in the same period last year[24]. - Cash inflow from investment activities was ¥152,158,992.83, significantly higher than ¥41,035,518.00 in Q3 2023, marking an increase of 270%[24]. - Cash inflow from financing activities reached ¥377,680,678.00, up 42.3% from ¥265,369,428.54 in Q3 2023[24]. - The company paid ¥315,089,308.18 in dividends and interest, an increase of 43.5% compared to ¥219,402,461.84 in Q3 2023[24]. Operational Highlights - Accounts receivable increased by 58.92% to ¥751,449,300.00, primarily due to increased sales revenue[7]. - The company reported a significant increase in prepayments, which rose by 506.32% to ¥24,985,700.00, attributed to higher procurement and R&D expenses[7]. - Short-term borrowings increased by 87.32% to ¥361,647,900.00, indicating a rise in financing activities[7]. - The revenue from the Wuling series increased by 24.88% year-on-year, driven by a 30.24% increase in sales volume and a 22.67% increase in sales amount for Wuling capsules, and a 37.05% increase in sales volume and a 36.90% increase in sales amount for Lingze tablets[9]. - The sales revenue from traditional Chinese medicine decoction pieces grew by 51.24% year-on-year, while the sales revenue from Chinese medicine formula granules surged by 175.96% year-on-year due to an increase in registered varieties[9]. - The operating costs for the year-to-date period reached 785.11 million yuan, an increase of 70.93% year-on-year, primarily due to rising costs associated with increased sales revenue[9]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,613[11]. - The largest shareholder, Yu Youqiang, holds 18.52% of the shares, with 64.5 million shares pledged[12]. - The total number of restricted shares held by major shareholders at the beginning of the period was 1,378,901, with 601,515 shares released and 262,879 shares added, resulting in 1,040,265 restricted shares at the end of the period[14]. - The controlling shareholder, Yu Youqiang, has pledged 64,500,000 shares, accounting for 49.66% of his holdings and 9.20% of the company's total share capital[15]. Future Plans - The company plans to continue investing in projects such as the "Intelligent Traditional Chinese Medicine Production Base" and "Innovative Pharmaceutical Industrialization Project" to support future growth[7]. - The company plans to implement an equity incentive plan funded by the share repurchase[16]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[16].

公司始终秉承"辅佐人类身体健康，致力祖国医药发展"的使命，倡导"创 新、奉献、卓越、合作、共赢"的核心价值观，坚持以乌灵系列产品为起点，以 药用真菌的产业化为己任，打造国内大型药用真菌制药领域的领头雁。公司主营 业务产品包括乌灵系列、百令系列、中药饮片及中药配方颗粒、聚卡波非钙片等， 近年来，乌灵胶囊入选浙江省首批"浙产名药"、首批"浙产中药"产业品牌， 产品影响力进一步扩大。根据米内网发布的年度中国医药市场发展蓝皮书，近三 年乌灵胶囊作为神经系统疾病用药在城市公立医院及县级公立医院的中成药用 药市场的市占率均为第一。未来公司将继续坚持"一体两翼"的战略目标，继续 深耕主业，聚焦营销，持续推进渠道开拓和品牌建设，深挖新的增长点；聚焦研 发，明确未来研发方向和战略，加大科技创新和新产品研发投入，丰富产品管线， 同时强化研发项目管理，加强人才体系建设，加速科技成果转化，提升核心竞争 力。 2024 年 1-6 月，公司实现营业收入 142,825.47 万元，较上年同期增长 41.21%；实现利润总额 34,426.94 万元，较上年同期增长 50.53%；归属于上市 证券代码：300181 证券简称：佐力药业 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% relative to the industry index within the next six months [8]. Core Views - The company is projected to achieve a net profit attributable to shareholders of approximately 411 to 426 million yuan for the first three quarters of 2024, representing a year-on-year increase of 43.29% to 48.52% [2]. - The company has actively repurchased shares, acquiring 2.12% of its total shares from August 13 to September 6, with a total expenditure of 204 million yuan, reflecting strong operational confidence [2]. - The core products, including Wuling Capsules and Lingze Tablets, continue to show robust growth, with significant sales increases driven by strategic marketing and product positioning [2]. Financial Summary - For 2024, the company expects to generate revenue of 2.466 billion yuan, with a year-on-year growth rate of 26.9% [3]. - The projected net profit for 2024 is estimated at 528 million yuan, reflecting a year-on-year growth of 37.8% [3]. - The company's return on equity (ROE) is expected to rise to 18.0% in 2024, indicating improved profitability [3]. - The earnings per share (EPS) is projected to reach 0.75 yuan in 2024, with a continuous upward trend in subsequent years [3]. Product and Market Strategy - The company is focusing on expanding its hospital coverage and enhancing its presence in the OTC market, utilizing a marketing strategy aimed at consumer education and product application [2]. - The Wuling Capsule, recognized as a national first-class new drug, has been recommended in 69 clinical pathways and guidelines, showcasing its established market position [2]. - The company is also developing a scientific and effective incentive plan for its employees, which is expected to further enhance operational performance [2].

浙江佐力药业股份有限公司 关于回购公司股份达到2%暨回购完成的公告 证券代码：300181 证券简称：佐力药业 公告编号：2024-063 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"）于 2024 年 7 月 26 日召开 第八届董事会第二次会议和第八届监事会第二次会议，审议通过了《关于回购公 司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司部分 人民币普通股（A 股）股份，用于后期实施股权激励计划。回购的资金总额不低 于人民币 20,000 万元（含）且不超过人民币 30,000 万元（含），回购股份价格 不超过人民币 20 元/股（含），回购股份的实施期限自董事会审议通过本次回购 股份方案之日起 6 个月内。在回购股份价格不超过 20 元/股的条件下，预计回购 股份数量约为 1,000 万股至 1,500 万股，约占公司已发行总股本的比例为 1.43% 至 2.14%，具体回购股份的数量以回购期限届满或回购实施完成时实际回购的股 份数量为准。具体内容详见公司于 2024 年 7 月 29 日 ...

浙江佐力药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | ☑ 现场参观 | | | | 其他 | | | 参与单位名称及 | | 海富通基金：高通、刘海啸；国金证券：王奔奔；光大证券： | | 人员姓名 | | 黄素青；国盛证券：胡偌碧；长安基金：朱施乐；大成基金： 杨挺；嘉实基金：邓云龙；天弘基金：刘盟盟；淡水泉：吴竞 尧；盘京投资：曹姗姗；中大君悦：熊文说。 | | | | | | 时间 | 2024 年 8 月 ...

证券代码：300181 证券简称：佐力药业 公告编号：2024-062 浙江佐力药业股份有限公司 1、公司未在下列期间以集中竞价交易方式回购公司股份： （1）自可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； （2）中国证监会规定的其他情形。 关于回购公司股份比例达到1%暨回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"）于 2024 年 7 月 26 日召开 第八届董事会第二次会议和第八届监事会第二次会议，审议通过了《关于回购公 司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司部分 人民币普通股（A 股）股份，用于后期实施股权激励计划。回购的资金总额不低 于人民币 20,000 万元（含）且不超过人民币 30,000 万元（含），回购股份价格 不超过人民币 20 元/股（含），回购股份的实施期限自董事会审议通过本次回购 股份方案之日起 6 个月内。在回购股份价格不超过 20 元/股的条件下，预计回购 股份数量约为 1,000 万股 ...

Investment Rating - The investment rating for the company is "Buy" [2][7]. Core Insights - The company's core products are maintaining steady growth, with significant revenue contributions from the unique Wuling series products [3][4]. - The company achieved a revenue of 1.428 billion yuan in H1 2024, representing a year-on-year growth of 41.21%, and a net profit of 296 million yuan, up 49.78% year-on-year [3]. - The rapid growth of traditional Chinese medicine (TCM) decoction pieces has become a new growth driver for the company, with H1 2024 revenue growth of 57.11% [5][6]. Financial Performance - In H1 2024, the Wuling series products generated 836 million yuan in revenue, accounting for 58.56% of total revenue and 81.14% of gross profit [3]. - The company expects revenues of 2.388 billion yuan, 2.926 billion yuan, and 3.503 billion yuan for the years 2024, 2025, and 2026, respectively, with net profits projected at 498 million yuan, 643 million yuan, and 794 million yuan [7][9]. - The gross margin is expected to improve from 68.4% in 2023 to 71.3% by 2026 [9]. Product Analysis - The Wuling series products, including Wuling capsules, are unique and have shown a consistent average growth rate of 26% from 2020 to 2023 [3]. - The Bailing series products are recovering, with H1 2024 revenue of 82 million yuan, a decrease of 16.59%, but the decline is narrowing [4]. - The company has over 1,000 varieties of TCM decoction pieces and has established more than 100 cooperative TCM material planting bases [5][6]. Market Strategy - The company is adopting a comprehensive sales model combining self-operated and commissioned sales across hospital, OTC, and online channels [4]. - The marketing strategy upgrade has shown significant effects, leading to increased sales in OTC and online markets [7].